

30 November 2011

The Manager
 Company Announcements Office
 ASX Limited
 20 Bridge St
 SYDNEY NSW 2000

RESULTS OF ANNUAL GENERAL MEETING

We wish to advise that resolutions put to the Annual General Meeting of CBio Limited held on Tuesday 29 November 2011 were each passed on a show of hands.

In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations Act, we advise details of the resolutions and the proxies received in respect of each resolution as follows:-

	Total number of votes	For the resolution	At proxy's discretion	Against resolution	Abstain from resolution
Resolution 1					
Remuneration Report	146,276,293	138,475,798	1,271,479	4,961,792	1,567,224
Resolution 2					
Withdrawn	-	-	-	-	-
Resolution 3					
Withdrawn	-	-	-	-	-
Resolution 4					
Election of Dr Terje Kalland	172,096,517	164,215,066	1,666,411	6,183,448	31,592
Resolution 5					
Election of Dr Thomas Lonngren	172,096,517	164,343,924	1,676,411	6,044,590	31,592
Resolution 6					
Withdrawn	-	-	-	-	-
Resolution 7					
Withdrawn	-	-	-	-	-

For and on behalf of the Board of CBio Limited

Roslynn Shand
 Company Secretary

About CBio Limited

CBio is an Australian ASX listed company established in 2000. CBio's lead product XToll is a potential new-generation drug therapy which could provide safer and more effective treatment of autoimmune diseases such as rheumatoid arthritis (RA) and lupus.

Enquiries

Melanie Farris
Communications and Corporate Affairs Manager
CBio Limited
T: +61 (0)449 148 448
melanie.farris@cbio.com.au